What's Next in the Pipeline
Version of Record online: 16 SEP 2008
© 2008 The Authors Journal compilation © 2008 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 8, Issue 10, pages 1972–1981, October 2008
How to Cite
Vincenti, F. and Kirk, A. D. (2008), What's Next in the Pipeline. American Journal of Transplantation, 8: 1972–1981. doi: 10.1111/j.1600-6143.2008.02403.x
- Issue online: 16 SEP 2008
- Version of Record online: 16 SEP 2008
- Received 30 June 2008, revised 31 July 2008 and accepted for publication 05 August 2008
- 6ISA247: A phase IIB multicenter, open label, concentration-controlled trial in de novo renal transplantation. (abstract LB06) Am J Transplant 2008; 8(Suppl 2): 336., , , , , .
- 11CP-690,550, a JAK3 inhibitor, in de novo kidney transplant recipients: 6-month results of a phase 2 trial (abstract). Am J Transplant 2007; 7(Suppl 2): 304., , et al.
- 13Enzymatic and cellular characterization of NVP-AEB071 (AEB), a novel and selective protein kinase C (PKC) inhibitor that blocks early T cell activation, and its use to define the role of PKC in T cells (abstract). Am J Transplant 2006; 7(Suppl 2): 1026., , et al.
- 14NVP-AEB071 (AEB), a novel protein kinase C inhibitor, abrogates early mouse T cell activation without affecting activation induced cell death (abstract). Am J Transplant 2006; 6(Suppl 2): 1029., , et al.
- 15NVP-AEB071 (AEB), a novel oral inhibitor of early T-cell activation, prolongs rat cardiac allograft survival when used alone and in combination with cyclosporine, Everolimus or FTY720 (abstract). Am J Transplant 2006; 6: 316., , et al.
- 16The first-in-class oral protein kinase C (PKC) inhibitor NVP-AEB071 (AEB) prolongs renal allograft survival in non-human primates and suppresses lymphocyte proliferation at safe exposures in human proof-of-concent studies (abstract). Am J Transplant 2006; 6(Suppl 2): 86., , et al.
- 17NVP-AEB071 (AEB), a novel oral inhibitor of early T-cell activation, prolongs the survival of non-human primate kidney allografts when used a monotherapy or at non-effective doses combined with a non-effective dose of cyclosporine (abstract). Am J Transplant 2006; 6(Suppl 2): 250., , et al.
- 18NVP-AEB071 (AEB), the novel oral inhibitor of protein kinase C and early T-cell activation, prolongs non-human primates kidney allograft survival when combined with Everolimus, ERL080 or FTY720 without calcineurin inhibitor (abstract). Am J Transplant 2006; 6(Suppl 2): 251., , et al.
- 19AEB071: Safety and activity of a novel T-cell activation inhibitor in psoriasis patients (abstract 1725). Presented at the 2007 American Transplant Congress; May 5–9, 2007; San Francisco , CA, USA ., , et al.
- 20Chronic induction: What's new in the pipeline. In: RoncoC, ChiaramonteS, RemuzziG, eds. Kidney transplantation: Strategies to prevent organ rejection. Basel , Switzerland : Karger, 2005: 22–29..
- 29Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation (abstract). Am J Transplant 2001; 1(Suppl 1): 191., , et al.
- 30A novel human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys, effect of induction and maintenance therapy (abstract #3). Amer J Transplant 7(Suppl 2): 147., , et al.
- 34Islet allograft survival in type 1 diabetics using a calcineurin-free protocol based on efalizumab and sirolimus (abstract #216). Am J Transplant 2008; 8(Suppl 2): 235., , et al.
- 35Clinical response to alefacept: Results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. European Acad Dermatol and Verereology 2003; 17(Suppl 2): 17–24..
- 36Targeting of costimulation blockade resistant T effector memory (TEM) cells in non-human primate renal transplantation with LFA-3-Ig (Alefacept) prolongs allograft survival (abstract 94). 2008; 8(Suppl 2): 204., , et al.
- 38Alefacept (LFA3-Ig), portal venous donor specific transfusion, and sirolimus prolong renal allograft survival in non-human primates (abstract #1627). Presented at World Transplant Congress July 24, 2006., , , , , .
- 51Pre-clinical assessment of Genz-29155, a novel small molecule inhibitor of apoptosis with anti-rejection effects in non-human primates [Abstract #192]. Amer J Transplant 2008; 8(Suppl 2): 229., , et al.